Hologic, Inc. (HOLX)

low relative PE, good star & 2010 earnings. Bottom fishing week of 11/9

Hopping on with takover rumors should push the stock to at least $25

Digital breast radiography and women's health. A company with a lot of debt, serial acquirer. Overpaid for cytec. This is not a company that fits into my real$ portfolio, but I'm willing to hold it for CAPS. If it ever turns positive for me on CAPS, I will sell as soon as I notice it. Props to KitKat for write-up. http://boards.fool.com/Message.asp?mid=27670964

demand great for product

HOLX

As usual, market has overly punished a strong company due to (slightly) decreased guidance. Don't expect the price of HOLX to go much lower than this. Ever.

Beaten down over their recent $2.34 billion write-down. Their technology stands as the best in their industry. Quite simply the stock is worth around $19-2o. At such a low price, a buyout seems very plausible given their bondholders current situation.

Stock is down 22% today, giving an excellent entry point. This is an over reaction to a quarterly report in which earnings beat again, and the company delivered $103m FCF despite a strong dollar and weak hospital environment. Overlooked is the continued growth in disposables, high margins, approval of 2 HPV tests (branded as Cervista) which will have a major impact in fiscal 2010. Also awaiting FDA approval is a 3D imaging system called Tomosynthesis, which has enormous potential once hospital budgets free up. The stock is now selling at less than 7x cash flow.

FDA approved two HPV tests. Clinician groups already indicating that these will be required tests.

healthcare $ go to good co's

Hologic has a very healthy market share for women's care products, including ThinPrep pap smears and Novasure endometrial ablation devices which treats abnormal bleeding on an outpatient basis. With a HPV diagnostic test awaiting FDA approval and new HPV testing recommendations, I expect this company to grow.

ANOTHER GREAT HEALTHCARE STOCK THAT SHOULD GROW IN 09. KEEP A WATCH & BUY & HOLD IF THINGS LOOK RIGHT IN MID TO LATE 09. THEN BUY & HOLD!!!!!!!!!

Woman's health care is getting huge. This company has great products and has made some key acquisitions. Will take some time.

On 11/18/08, a 5 star stock that is down more than 60 % from its yearly high but recent momentum.

Biotech sector will et a boost from Obama

As the worldwide middle class grows demand for health care will increase as will demand for HOLX cutting edge products.

Excellent earnings even in a tough economy. Very undervalued and the reduced outlook on 2008 earnings is nothing to get up in arms about. The financials are simply too solid to pass up.

Undervalued

A rapidly growing medical device company which is forecast to have significant profit growth selling at the low-end of its price range and showing heavy insider-buying by CEO, CFO & president.